Cytomed Therapeutics (GDTC)Director bought ~$150K

~$150K

Approx. value · 100K sh @ $1.50

630K

Holds after · shares reported

Traded

Jul 20, 2026

Filed

Jul 25, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 13, 2026InsiderDirector purchased ~$129K of GDTC shares in the open market
2. Jul 14, 2026InsiderDirector purchased ~$150K of GDTC shares in the open market
3. Jul 20, 2026 · this disclosureInsiderDirector purchased ~$150K of GDTC shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cytomed Therapeutics

For Cytomed Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GDTC page.

Other recent filings by Chee Kong Choo, Director

• SEC Form 4 at Cytomed Therapeutics (GDTC)Jul 25, 2026
• SEC Form 4 at Cytomed Therapeutics (GDTC)Jun 15, 2026

The full history of Chee Kong Choo, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Cytomed Therapeutics

• SEC Form 4Jul 25, 2026
• SEC Form 4Jun 15, 2026

Everything OQRO holds on this company is on its GDTC page.